ARGENX Reports Record 2025 Financials with $4.2B Sales, $1.3B Profit; Advances Key VYVGART Regulatory Milestones

summarizeSummary

ARGENX SE announced exceptional full-year 2025 financial results, including a 90% increase in product net sales to $4.2 billion and a significant swing to $1.3 billion in profit, alongside critical regulatory advancements for its VYVGART franchise.

check_boxKey Events

• Record Financial Performance

  Product net sales surged 90% to $4.2 billion in 2025, with the company achieving its first full year of operational profitability at $1.05 billion and a net profit of $1.3 billion, significantly reducing accumulated losses to $0.3 billion.

• VYVGART Commercial Success

  The VYVGART franchise surpassed $1 billion in quarterly net sales for the first time in Q3 2025, driven by the successful launch of the VYVGART HYTRULO pre-filled syringe in the U.S., EU, and Japan.

• Key Regulatory Milestones Achieved

  The supplemental Biologics License Application (sBLA) for VYVGART in seronegative generalized myasthenia gravis (gMG) was accepted for priority review by the FDA with a PDUFA date of May 10, 2026, following positive topline data in 2025. Additionally, positive data from the ADAPT OCULUS clinical trial in ocular myasthenia gravis (oMG) was reported in February 2026.

• Robust Pipeline Advancement

  The company has 10 ongoing registrational clinical trials and brought four new molecules into the pipeline in 2025, with multiple pivotal data readouts expected in 2026 (Myositis, MMN, ITP) and 2027 (SjD, CIDP).

auto_awesomeAnalysis

ARGENX SE delivered an exceptionally strong full-year 2025 performance, marked by substantial revenue growth and a significant swing to profitability. The company's flagship VYVGART franchise demonstrated robust commercial execution, surpassing a billion dollars in quarterly sales and expanding its market reach with new formulations. Critically, the company achieved significant regulatory milestones for VYVGART, including priority review for seronegative gMG and positive data for ocular MG, which are expected to drive further label expansion and market penetration. The extensive pipeline, with multiple registrational readouts anticipated in 2026 and 2027, underscores a strong growth trajectory. This filing provides a comprehensive positive update on both financial health and strategic product development, reinforcing the company's long-term investment thesis.